Latest From NodThera Ltd.
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
- Therapeutic Areas
- Immune Disorders
- Western Europe
- Company Type
- Parent & Subsidiaries
- NodThera Ltd.
- Senior Management
Alan Watt, PhD, MBA, CSO
Chris Gabel, PhD, VP, Biology
Mark Bock, PhD, VP, Medicinal Chemistry
David Harrison, MChem, Director, Medicinal Chemistry
Valerie Reader, MSc, Head, Ops
- Contact Info
Phone: 7928 555460
Chesterford Research Park, Suite 8
Little Chesterford, CB10 1XL
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.